Kelly Louise Morrison, U.S. Representative

Kelly Louise Morrison

DemocratMN03houseFiled Apr 11, 2025
24 total filings on record
Trades
18
Tickers
7
Max Value
$15K-$50K
Timing Flags
5

Price Movement Since Trade

How each stock has moved from the trade date to the most recent close.

Infrastructure & Construction
$MRK✗ BAD SELL
Health Care
Trade Day
$94.73
Mar 20, 2025
Current
$111.90
Apr 24, 2026
Change
+18.13%
+$17.17
Transportation & Logistics

Suspicious Timing Detected

5 flags
1.

Representative Morrison bought $15,001-$50,000 in $META on March 24, 2025, one day before the "United States Leadership in Immersive Technology Act of 2025" (HR2321) was introduced, a bill potentially relevant to Meta Platforms, Inc.

2.

Representative Morrison sold $1,001-$15,000 in $DHI on March 20, 2025, seven days before the "Revitalizing Downtowns and Main Streets Act" (HR2410) was introduced, a bill that could impact the housing sector.

3.

Representative Morrison sold $1,001-$15,000 in $UPS on March 20, 2025, 20 days before the "Protecting Employees and Retirees in Business Bankruptcies Act of 2025" (S1381) was introduced, a bill aiming to increase corporate liability.

4.

Representative Morrison sold $1,001-$15,000 in $MRK on March 20, 2025, 21 days before the "ABC Safe Drug Act" (S1407) was introduced, a bill that aims to restrict federal funding for certain drug-related activities.

5.

Representative Morrison sold $1,001-$15,000 in $CACI on March 20, 2025, 35 days before the "Homeland Security Climate Change Coordination Act" (HR3002) was introduced, a bill establishing a DHS climate change office.

These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.

Share This Filing

All Transactions

BUY$15K-$50K
$METAMeta Platforms, Inc. - Class A Common Stock (META) [ST]
$618.85 \u2192 N/A
Mar 24, 2025 \u2022 self
BUY$15K-$50K
Government SecuritiesUS Treasury Note DTD 02/28/26 [GS]
Mar 4, 2025 \u2022 self
BUY$1K-$15K
$AVGOBroadcom Inc. - Common Stock (AVGO) [ST]
Mar 21, 2025 \u2022 self
BUY$1K-$15K
$AVGOBroadcom Inc. - Common Stock (AVGO) [ST]
Mar 21, 2025 \u2022 self
BUY$1K-$15K
$METAMeta Platforms, Inc. - Class A Common Stock (META) [ST]
$618.85 \u2192 N/A
Mar 24, 2025 \u2022 self
BUY$1K-$15K
$METAMeta Platforms, Inc. - Class A Common Stock (META) [ST]
$618.85 \u2192 N/A
Mar 24, 2025 \u2022 self
SELL$1K-$15K
$CACICACI International, Inc. Class A Common Stock (CACI) [ST]
$369.66 \u2192 N/A
Mar 20, 2025 \u2022 self
SELL$1K-$15K
$CACICACI International, Inc. Class A Common Stock (CACI) [ST]
$369.66 \u2192 N/A
Mar 20, 2025 \u2022 self
SELL$1K-$15K
$CACICACI International, Inc. Class A Common Stock (CACI) [ST]
$369.66 \u2192 N/A
Mar 20, 2025 \u2022 self
PARTIAL SELL$1K-$15K
$DHID.R. Horton, Inc. Common Stock (DHI) [ST]
$131.13 \u2192 N/A
Mar 20, 2025 \u2022 self

Connected Legislative Activity

10 signals

These bills and contracts share tickers or sectors with this filing's trades.

BillHR2321neutral

United States Leadership in Immersive Technology Act of 2025

HR2321 (United States Leadership in Immersive Technology Act of 2025) is an early-stage bill referred to committee in March 2025. It establishes a purely advisory panel with no funding authorizations or appropriations, creating zero near-term financial impact on any public company.

Mar 25, 2025
METANVDAQCOM
BillS1407neutral

ABC Safe Drug Act

The ABC Safe Drug Act (S. 1407) is in early legislative stages, having been referred to the Senate Finance Committee. It phases in restrictions on federal health programs purchasing drugs with Chinese active ingredients by 2030 and provides temporary tax incentives for domestic pharmaceutical manufacturing. Major pharma stocks ($PFE, $MRK, $JNJ, $LLY, $AMGN) show mixed but broadly negative 7-day changes, reflecting sector headwinds rather than this nascent bill. No market-moving impact is imminent.

Apr 10, 2025
AMGNLLYMRKPFE
BillHR1970bullish

Providing Veterans Essential Medications Act

HR1970 (Providing Veterans Essential Medications Act) is in early legislative stages, having been referred to the House Veterans' Affairs subcommittee. The bill mandates VA reimbursement for high-cost medications dispensed to veterans in State nursing homes, but authorizes no specific funding and remains months from passage. Real market data shows CVS up 16% in 30 days while CAH is down 10%, reflecting broader distribution-sector dynamics rather than this early-stage bill.

Mar 27, 2025
CAH
BillS860neutral

BUST FENTANYL Act

The BUST FENTANYL Act (S860) is a procedural bill that mandates new intelligence reports on fentanyl trafficking but authorizes zero new funding. The bill provides mild tailwinds for government contractors like $PLTR, $CACI, and $SAIC through existing contract vehicles, but near-term revenue impact is capped by the lack of appropriations. All three stocks have declined 4-6% in the past 30 days, reflecting broader sector weakness rather than legislative catalysts.

Apr 28, 2025
CACIPLTRSAIC
BillS1381bearish

Protecting Employees and Retirees in Business Bankruptcies Act of 2025

S. 1381 (Protecting Employees and Retirees in Business Bankruptcies Act of 2025) is an early-stage Senate bill that would structurally increase bankruptcy costs for labor-intensive companies. For UAL and GM, the bill elevates employee and retiree claims in Chapter 11, raising bankruptcy risk premiums. At impact score 3, near-term market effects are minimal, but the structural risk is real if the bill advances through the Judiciary Committee.

Apr 9, 2025
GMUAL
BillHR2767neutral

BRAIN Act

The BRAIN Act (HR2767) is an early-stage bill in the 119th Congress that authorizes no funding and has been referred to committee. Near-term market impact is negligible. The bill creates programmatic structures for brain tumor research, biospecimen transparency, and biomarker testing awareness, but actual market effects require future appropriations and bill text clarity. No publicly traded companies face material revenue exposure at this stage.

Apr 9, 2025
BillS1396neutral

Content Origin Protection and Integrity from Edited and Deepfaked Media Act of 2025

S. 1396 (Content Origin Protection Act) is an early-stage bill requiring content provenance labeling for AI-generated content. It has not advanced beyond committee since April 2025 and carries no authorized funding. Adobe ($ADBE) is structurally positioned as a beneficiary if the bill gains momentum due to its existing C2PA/Content Credentials alignment, but the legislative path is long and uncertain. Major platform operators (GOOGL, META, MSFT, AMZN) face compliance costs that are immaterial relative to their scale.

Apr 9, 2025
ADBEAMZNGOOGL
BillHR2410neutral

Revitalizing Downtowns and Main Streets Act

HR2410, the Revitalizing Downtowns and Main Streets Act, proposes a 20% tax credit for converting non-residential buildings into affordable housing. Introduced March 27, 2025, it remains in early legislative stages in the House Ways and Means Committee with no near-term market impact. Monitored homebuilders ($LEN, $DHI, $PHM, $KBH, $NVR) show neutral direct exposure; real beneficiaries would be commercial real estate owners and adaptive reuse developers not represented in this ticker set.

Mar 27, 2025
BXPSLG
BillS1515bullish

Affordable Housing Credit Improvement Act of 2025

The Affordable Housing Credit Improvement Act of 2025 (S.1515) is early-stage legislation that would expand the LIHTC program, the primary federal subsidy for affordable rental housing. If enacted, it directly benefits major homebuilders with multifamily divisions ($LEN, $DHI, $PHM, $KBH, $TOL) by increasing the supply of development capital. Major bank tax equity investors ($JPM, $WFC, $BAC, $C) also benefit from expanded syndication volume.

Apr 29, 2025
BACCDHIJPMKBHLEN
BillHR3002neutral

Homeland Security Climate Change Coordination Act

HR3002, the Homeland Security Climate Change Coordination Act, is an early-stage House bill creating a DHS internal council to coordinate climate adaptation efforts. It authorizes zero funding, no procurement, and no regulatory changes, producing no measurable near-term market impact for any public company. The bill is stuck in subcommittee with no further action since introduction over a year ago.

Apr 24, 2025

Other Filings by Kelly Louise Morrison

Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.